Institut Clinique de la Souris
The Institut Clinique de la Souris (ICS) is an infrastructure of excellence in translational research and functional genomics. Genetic researches are conducted and supported combining generation and validation of mutant mice model and comprehensive phenotypic analysis (physiological -behavioral – anatomical).
ICS provides scientists with a broad set of highly specialized mouse services. It consists in three highly interactive departments, Genetic Engineering and Model Validation, Phenotyping and Mouse Supporting Services which generate approximately 200 genetically modified mice per year.
ICS is a reference centre regarding animal models for human pathologies. It contributes to their better understanding and supports the generation of novel therapeutics. It develops and shares relevant research and development program through the PHENOMIN project which federates French teams of excellence in mouse genetics (Strasbourg, Orléans, Marseille and Villejuif). The goal is to give birth to a national infrastructure specialized in development, characterization and conservation of mice models.
For more information please go to www.ics-mci.fr
GenOway (ALTERNEXT-NYSE: ALGEN) is a biotechnology company developing genetically modified and high value-added research models for the bio-pharmaceutical, chemical, agrochemical and food industry as well as for academic research. With highly qualified scientific personnel, the company has a work force of 60 people and operates in over 22 countries in Europe, Asia and North America, supplying more than 275 customers. genOway is a leader in its market in terms of both size and customer portfolios.
The company’s development is founded upon both a broad and exclusive technology platform as well as strong intellectual property rights combining patents and licensing agreements. Taking advantage of the global trend towards outsourcing the production of genetically modified research models, genOway has signed many contracts with leaders of the pharmaceutical industry (Pfizer, Bayer, Boehringer Ingelheim, etc.), and with the most prestigious academic research centers (King’s College and the University of Manchester, in England; Duke University and the National Institutes of Health, in the United States; the Institut Pasteur, in France; NGFN and the Max Planck Institutes, in Germany, etc.).
To strengthen its technological position and benefit from worldwide business partners, genOway has signed strategic alliances with leading companies in their field: Charles River Laboratories (NYSE: CRL, a world leader in supplying laboratory animals), Invitrogen (NASDAQ: IVGN, world leader in supplying molecular biology reagents).
For more information please go to www.genoway.com.